The funding agency aims to cap “indirect costs” in biomedical research grants. But this behind-the-scenes work is crucial to making research happen.

Mesoblast's high-risk programs drive inflated valuation. Find out why MESO stock remains a "sell" as execution risks outweigh ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Zydus Lifesciences Ltd on Friday announced that the United States Food and Drug Administration (USFDA) has completed an inspection at its facility in Ahmedabad with nil observations. – Net Profit Up ...